Volume 1, Issue 1, June 2017, Page: 4-5
Nanomedicine for Treatment of Cancer
Yuan Sun, Department of Chemistry and Biochemistry, The Ohio State University, Columbus, OH, USA
Xiao Zhong, Molecular Design Institute, Department of Chemistry, New York University, NY, USA
Chen Kang, Division of Pharmacology, College of Pharmacy, The Ohio State University, Columbus, OH, USA
Received: Apr. 27, 2016;       Accepted: Jun. 3, 2016;       Published: Jun. 17, 2016
DOI: 10.11648/j.pst.20170101.12      View  2480      Downloads  150
Abstract
Keywords
To cite this article
Yuan Sun, Xiao Zhong, Chen Kang, Nanomedicine for Treatment of Cancer, Pharmaceutical Science and Technology. Vol. 1, No. 1, 2017, pp. 4-5. doi: 10.11648/j.pst.20170101.12
Copyright
Copyright © 2016 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians, 2016; 66: 7-30.
[2]
Livingston RB. Single agents in cancer chemotherapy. Springer Science & Business Media 2012.
[3]
Vanneman M, Dranoff G. Combining immunotherapy and targeted therapies in cancer treatment. Nature Reviews Cancer, 2012; 12: 237-251.
[4]
Plenderleith IH. Treating the treatment: toxicity of cancer chemotherapy. Canadian Family Physician, 1990; 36: 1827.
[5]
Bae YH, Park K. Targeted drug delivery to tumors: myths, reality and possibility. Journal of Controlled Release, 2011; 153: 198.
[6]
Lee S-H, Roichman Y, Yi G-R, Kim S-H, Yang S-M, van Blaaderen A, van Oostrum P, Grier DG. Characterizing and tracking single colloidal particles with video holographic microscopy. Optics Express, 2007; 15: 18275-18282.
[7]
Wang C, Zhong X, Ruffner DB, Stutt A, Philips LA, Ward MD, Grier DG. Holographic characterization of protein aggregates. Journal of pharmaceutical sciences, 2016; 105: 1074-1085.
[8]
Fenske DB, Chonn A, Cullis PR. Liposomal nanomedicines: an emerging field. Toxicologic pathology, 2008; 36: 21-29.
[9]
Kang C, Sun Y, Wang M, Cheng X. Nanosized Camptothecin Conjugates for Single and Combined Drug Delivery. European Journal of BioMedical Research, 2016; 2: 8-14.
[10]
Kim SH, Kaplan JA, Sun Y, Shieh A, Sun HL, Croce CM, Grinstaff MW, Parquette JR. The Self‐Assembly of Anticancer Camptothecin–Dipeptide Nanotubes: A Minimalistic and High Drug Loading Approach to Increased Efficacy. Chemistry–A European Journal, 2015; 21: 101-105.
[11]
Sun Y, Kaplan JA, Shieh A, Sun H-L, Croce CM, Grinstaff MW, Parquette JR. Self-assembly of a 5-fluorouracil-dipeptide hydrogel. Chemical Communications, 2016; 52: 5254-5257.
[12]
Green M, Manikhas G, Orlov S, Afanasyev B, Makhson A, Bhar P, Hawkins M. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Annals of Oncology, 2006; 17: 1263-1268.
[13]
Linkov I, Satterstrom FK, Corey LM. Nanotoxicology and nanomedicine: making hard decisions. Nanomedicine: Nanotechnology, Biology and Medicine, 2008; 4: 167-171.
Browse journals by subject